Key result
Peptic ulcer disease increased the incidence of hyperlipidemia compared to no PUD, whereas the use of anti-PUD medications was associated with a lower risk.
Why the study?
The connection between peptic ulcer disease and hyperlipidemia was unclear, with a lack of thorough studies investigating the impact of anti-peptic ulcer medications on hyperlipidemia risk, particularly in Asian populations.
Do anti-PUD medications reduce the risk of developing hyperlipidemia in patients with peptic ulcer disease?
Cohort
Do anti-PUD medications reduce the risk of developing hyperlipidemia in patients with peptic ulcer disease?
Answers are grounded in this paper and cite their sources.
Peptic ulcer disease is associated with an increased risk of developing hyperlipidemia, but treatment with anti-PUD medications appears to mitigate this risk.
Background: The causes of cardiovascular disease are complex, with hyperlipidemia being a major factor in its development. The connection between peptic ulcer disease (PUD) and hyperlipidemia is unclear, and there have been no thorough studies on the effect of anti-PUD medications on the risk of hyperlipidemia, particularly in Asian populations. This study aimed to explore the relationship among PUD, anti-PUD medications, and the risk of developing hyperlipidemia. Objectives: Utilizing a population-based cohort study conducted in Taiwan, we investigated the association between PUD, the administration of anti-PUD medications, and the subsequent risk of developing hyperlipidemia. Design: Retrospective study. Methods: Using data from the Taiwan National Health Insurance Research Database, we conducted a 21-year follow-up study on patients diagnosed with PUD between 2000 and 2021. The Cox proportional hazards regression model was used to analyze the risk of developing hyperlipidemia in relation to PUD and the use of anti-PUD medications. Results: According to the multivariable Cox proportional hazards regression analysis, patients with PUD had a higher overall incidence of hyperlipidemia (80.7 vs 53.6 per 1000 person-years) than those without PUD. The adjusted hazard ratio was 1.64 (95% confidence interval = 1.62–1.67). Both men and women, as well as different age groups, showed a higher risk of hyperlipidemia among patients with PUD. Patients with PUD who undergo surgery have a higher risk of developing hyperlipidemia than those who do not. The use of anti-PUD medications, such as H2 receptor antagonists, proton pump inhibitors, antibiotics, prostaglandin analogs, anticholinergics, antacids, and carbenoxolone, but not bismuth salts, was associated with a lower risk of developing hyperlipidemia than non-use. Conclusion: Patients with PUD were more likely to develop hyperlipidemia. However, patients receiving anti-PUD medications had a lower incidence of hyperlipidemia.
No takes yet. Share an insight, caveat, or question.
Hsieh et al. (2026) conducted a cohort in Peptic ulcer disease (PUD). Peptic ulcer disease (PUD) and anti-PUD medications vs. Without PUD / Non-use of anti-PUD medications was evaluated on Incidence of hyperlipidemia (HR 1.64, 95% CI 1.62-1.67). Peptic ulcer disease increased the incidence of hyperlipidemia compared to no PUD, whereas the use of anti-PUD medications was associated with a lower risk.
Synapse has enriched 10 related papers. Consider them for comparative context: